Henan Meitaibao Biopharmaceutical Co., Ltd.

Primary objective: To evaluate the safety and tolerability of doxitinib mesylate tablets (90-1408) in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. Secondary objectives: To evaluate the pharmacokinetic (PK) characteristics of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations after single or multiple administrations; To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To determine the recommended dose (RP2D) of 90-1408 in the Phase II clinical study for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To evaluate the preliminary efficacy of 90-1408 in the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations; To explore the drug metabolism profile of 90-1408 in plasma and urine.